Claims
- 1. A method for treating benign prostatic hypertrophy which comprises administering, to a patient in need of such treatment, an effective 5.alpha.-reductase inhibitory amount of a compound of the formula: ##STR9## wherein R is hydrogen, C.sub.1-4 alkyl or C.sub.1-2 alkanoyl; R.sup.1 is C.sub.2-6 alkanoyl, -(C.sub.1-6 alkyl)-OZ.sup.2, -(C.sub.2-6 alkyl)-(OZ2)2 or -A-C(O)-Y; Z.sup.2 is hydrogen, C.sub.1-6 alkyl, phenyl-(C.sub.1-4 alkyl), (Y.sup.1 -substituted phenyl)-(C.sub.1-4 alkyl), C.sub.1-6 alkanoyl, benzoyl or Y.sup.1 -substituted benzoyl wherein Y.sup.1 is methyl, halogen or methoxy; A is absent or is present as an alkylene of 1 to 6 carbon atoms; Y is --OH, --O(C.sub.1-6 alkyl) or --NR.sup.3 R.sup.4 ; R.sup.2 is hydrogen; R.sup.3 and R.sup.4 are each independently hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or they can be combined to give -(CH.sub.2)n- wherein n is 4 to 6; R.sup.5 is hydrogen or methyl; X is O or (H) (H); Z is hydrogen or C.sub.1-6 alkyl; Z.sup.1 is hydrogen or methylene; and each of the dotted lines in the rings indicates the optional presence of a double bond with the proviso that a 9,11 double bond can only be present when X is H and the proviso that, when a 16,17 double bond is present then R.sup.2 is absent.
- 2. The method according to claim 1 which comprises administering 4-aminopregn-4-ene-3,20-dione.
- 3. The method according to claim 1 which comprises administering N,N-diisopropyl-4-amino-3-oxoandrost-4-ene-17.beta.-carboxamide.
- 4. The method according to claim 1 which comprises administering N-(t-butyl)-4-amino-3-oxoandrost-4-ene-17.beta.-carboxamide.
- 5. The method according to claim 1 which comprises administering (20S)-4-amino-21-hydroxy-20-methylpregn-4-en-3-one.
CROSS-REFERENCE TO RELATED APPLICATION
This is a division of application Ser. No. 07/980,932, filed Nov. 20, 1992, which is a divisional of 07/855,368, filed Mar. 20, 1992, now U.S. Pat. No, 5,218,110, which is a divisional of 07/720,900, filed Jul. 2, 1991, now U.S. Pat. No. 5,120,840, and that application is a continuation-in-part of both 07/561,041, filed Aug. 1, 1990, now abandoned and 07/671,555, filed Mar. 19, 1991, now U.S. Pat. No. 5,143,909.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
3637668 |
Laurent et al. |
Jan 1972 |
|
3780070 |
Shapiro |
Dec 1973 |
|
4757061 |
Faustini et al. |
Jul 1988 |
|
5143909 |
Weintraub et al. |
Sep 1992 |
|
Foreign Referenced Citations (5)
Number |
Date |
Country |
0260975 |
Sep 1987 |
EPX |
0286578 |
Mar 1988 |
EPX |
0291290 |
May 1988 |
EPX |
291290 |
Nov 1988 |
EPX |
2171100 |
Feb 1986 |
GBX |
Non-Patent Literature Citations (7)
Entry |
Drugs of the Future 1994, 19(7): 646-650; Steroid 5.alpha.-Reductase Inhibitor Treatment for Benign Prostatic Hyperplasia. |
Ekhato et al., J. Chem. Soc. Perkin Trans. 1, 1988, 3239. |
Chemical Abstracts, 64, 2142e (1966). |
Derwent Basic Abstract 9186 (JP 17673/63), 1963. |
Derwent Basic Abstract 11,765 (JP 4476/64), 1964. |
R. D. Lynch, "Synthesis and Chemistry of Steroidal Azido Ketones. Possible Photoaffinity Labels of Steroids Receptor Proteins," Ph.D. Dissertation (Vanderbilt University), Dec. 1977, pp. XIV, XV, 22, 26, 40, 41, 42, 95, and 96 Dec. 1, 1981. |
Zlobino M., Chemical Abstracts, vol. 106, No. 21, dated May 25, 1987. Abstract No. 176726. |
Related Publications (1)
|
Number |
Date |
Country |
|
671555 |
Mar 1991 |
|
Divisions (3)
|
Number |
Date |
Country |
Parent |
980932 |
Nov 1992 |
|
Parent |
855368 |
Mar 1992 |
|
Parent |
720900 |
Jul 1991 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
561041 |
Aug 1990 |
|